216.78 USD
↗ 2.43 (1.13%)AT CLOSE (11:59 AM EDT)
Biogen Inc. Common Stock
BIIBNASDAQ • USD
217.38
↗ 0.60 (0.27%)
POST MARKET (AS OF 07:31 PM EDT)
Post Market
AS OF 07:31 PM EDT
217.38
↗ 0.60 (0.27%)
Market: CLOSED
Biogen Inc. Common Stock (BIIB) is currently trading at $216.78. The stock presents a mixed profile: our models indicate a Strong Buy for technical indicators, while underlying fundamentals flash a Sell. Notable factors include a weak Piotroski F-Score of 2/9, a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation metrics place BIIB at a fair price relative to peers.
Technical & fundamental data as of Aug 21, 2026.
Open?$217.76
High?$219.12
Low?$215.00
Prev. Close?$214.35
Volume?722.3K
Avg. Volume?1.2M
VWAP?$217.35
Rel. Volume?0.63x
Bid / Ask
Bid?$215.01 × 100
Ask?$219.00 × 200
Spread?$3.99
Midpoint?$217.01
Valuation & Ratios
Market Cap?32.0B
Shares Out?147.8M
Float?147.4M
Float %?99.8%
P/E Ratio?38.38
P/B Ratio?1.70
EPS?$5.65
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Employees
7.5K
Market Cap
32.0B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
1991-09-17
Address
225 BINNEY STREET
CAMBRIDGE, MA 02142
Phone: (617) 679-2000
CAMBRIDGE, MA 02142
Phone: (617) 679-2000
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+1/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?12
Z-Score?69
Momentum?5
Short Sent.?74
Piotroski F-Score?2/9Weak
Altman Z-Score?2.93Grey
Confidence?62%Moderate
Short InterestModerate
Short % of Float?3.70%Low
Short Interest?5.5M
Days to Cover?4.7
Free Float147.4M
Avg Daily Volume1.2M
Settlement Date2026-07-31
Financial Health
Current Ratio?1.87Adequate
Quick Ratio?1.26Adequate
Cash Ratio?0.33Low
Debt/Equity?0.43Low
ValuationFAIRLY VALUEDvs 10 peers + S&P 500
Score72/100
P/E?38.4PRICEY▾
Peers50
S&P19
P/B?1.70CHEAP▾
Peers90
S&P82
P/S?3.19FAIR▾
Peers90
S&P48
P/FCF?11.9CHEAP▾
Peers100
S&P83
EV/EBITDA?16.9FAIR▾
Peers86
S&P38
EV/Sales?3.87FAIR▾
Peers80
S&P49
Returns & Efficiency
ROE?4.4%WEAK▾
Peers20
S&P19
ROA?2.6%WEAK▾
Peers17
S&P24
Cash Flow & Enterprise
FCF?$2.7B
Enterprise Value?$38.8B
Fundamentals ratios updated end of day